Delavirdine (DB00705): A Comprehensive Pharmacological and Clinical Monograph of a Second-Generation NNRTI

Introduction: Delavirdine in the Context of Antiretroviral Therapy

Delavirdine, marketed under the brand name Rescriptor, is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was approved by the U.S. Food and Drug Administration (FDA) in 1997 for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection.[1] As a component of the early Highly Active Antiretroviral Therapy (HAART) regimens, it represented a significant advancement by offering a mechanism of action distinct from the foundational nucleoside reverse transcriptase inhibitors (NRTIs). However, the clinical history of Delavirdine is defined by a central paradox: its unique pharmacological profile as a potent inhibitor of the cytochrome P450 (CYP) metabolic enzyme system created both therapeutic opportunities and profound clinical challenges. This dual nature as both an antiviral agent and a significant metabolic modulator ultimately dictated its limited clinical utility and eventual obsolescence in the face of more effective, tolerable, and pharmacologically simpler agents.[1]

The introduction of Delavirdine occurred during a period of transformative progress in HIV therapeutics. The mid-1990s saw the advent of protease inhibitors and NNRTIs, which, when combined with NRTIs, created the first truly effective regimens capable of durable viral suppression. Delavirdine entered this competitive landscape but was soon overshadowed by contemporaries, most notably efavirenz, which offered superior virologic efficacy and a more convenient once-daily dosing schedule.[1] Consequently, Delavirdine serves as an important case study in the evolution of antiretroviral drug development. Its lifecycle illustrates the relentless pursuit of improved efficacy, tolerability, convenience, and a manageable drug-drug interaction profile—factors that have become paramount in the long-term management of chronic viral infections like HIV.[4]

Delavirdine's unique position in the NNRTI class stemmed from its function as a significant metabolic inhibitor, a characteristic more commonly associated with protease inhibitors such as ritonavir. While other NNRTIs like nevirapine were primarily enzyme inducers, Delavirdine's potent inhibition of CYP3A4 presented a novel pharmacological property.[3] This created the potential to act as a pharmacokinetic enhancer, or "booster," for other antiretrovirals metabolized by this pathway, thereby increasing their systemic exposure.[3] However, this same mechanism was the source of a vast and complex web of drug-drug interactions, rendering its use with many common medications hazardous and complicating regimen management to a degree that was often clinically untenable.[1] The clinical burden of navigating these interactions ultimately outweighed the benefits of its modest antiviral activity and potential boosting effect. Thus, the story of Delavirdine is a cautionary tale in pharmacology, demonstrating with clarity that a drug's metabolic profile can be as decisive for its clinical success and longevity as its primary mechanism of action. This report provides a comprehensive monograph on Delavirdine, detailing its chemical properties, mechanism of action, pharmacokinetics, clinical application, safety profile, and the regulatory and market forces that led to its discontinuation.

Chemical Profile and Pharmacological Classification

Identification and Physicochemical Properties

Delavirdine is chemically identified as a bisheteroarylpiperazine derivative.[6] It is presented for clinical use as the mesylate salt.[1]

• Nomenclature:
• Generic Name: Delavirdine [1]
• Brand Name: Rescriptor [1]
• Synonyms/Codes: DLV, U 90152, U-90152, BHAP-U 90152 [10]
• Chemical Identifiers:
• DrugBank ID: DB00705 [1]
• CAS Number: 136817-59-9 (free base); 147221-93-0 (mesylate salt) [11]
• Molecular Formula: C22​H28​N6​O3​S [11]
• Molecular Weight: 456.56 g/mol (free base); 552.68 g/mol (mesylate salt) [11]
• IUPAC Name: N-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide [13]
• InChI: InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3 [1]
• InChIKey: WHBIGIKBNXZKFE-UHFFFAOYSA-N [1]
• SMILES: CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C [13]
• Structural Class and Physicochemical Properties: Delavirdine is structurally described as the amide formed from the condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and the 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine.13 Its structure incorporates several key functional groups, classifying it as an N-acylpiperazine, a sulfonamide, an aminopyridine, and an indolecarboxamide.13 As a mesylate salt, it is an odorless, white-to-tan crystalline powder.8 A critical physicochemical property is its pH-dependent aqueous solubility. It is relatively soluble in acidic conditions ( 2942μg/mL at pH 1.0) but demonstrates a sharp decrease in solubility as pH increases, becoming poorly soluble at neutral pH (0.81μg/mL at pH 7.4).[8] This property has direct and significant implications for its oral absorption and potential interactions with acid-reducing medications.

Mechanism of Action

Delavirdine is classified pharmacologically as a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.[13] Its antiviral effect is achieved through a mechanism of non-competitive, allosteric inhibition of the HIV-1 reverse transcriptase (RT) enzyme.[2]

The drug binds directly to a hydrophobic, non-substrate binding pocket on the p66 subunit of the HIV-1 RT enzyme.[8] This binding site is spatially distinct from the enzyme's active catalytic site where nucleoside triphosphates bind. The interaction of Delavirdine with this allosteric site induces a critical conformational change in the enzyme, disrupting the flexibility and positioning of key residues within the catalytic domain.[6] This structural disruption effectively inactivates the enzyme, blocking both its RNA-dependent and DNA-dependent DNA polymerase functions, which are essential for converting the viral RNA genome into proviral DNA for integration into the host cell's genome.[8] Because the mechanism is non-competitive, Delavirdine does not compete with the natural substrates (deoxynucleoside triphosphates) or the template-primer complex for binding to the enzyme.[8]

Antiviral Spectrum and Resistance

Delavirdine's antiviral activity is highly specific. It is a potent inhibitor of HIV-1 RT but lacks any significant activity against HIV-2 RT.[8] This specificity is a hallmark of the NNRTI class, as the allosteric binding pocket is not conserved between the two viral types. Furthermore, Delavirdine does not inhibit human cellular DNA polymerases, including polymerases alpha, beta, delta, or gamma, which accounts for its targeted antiviral effect and lack of myelosuppressive toxicity commonly associated with older NRTIs.[8] It is noted that certain highly divergent strains of HIV-1, such as those belonging to group O, may not be susceptible to Delavirdine.[17]

A critical limitation of Delavirdine, and all NNRTIs, is the low genetic barrier to resistance. Viral resistance emerges rapidly when Delavirdine is administered as monotherapy.[8] This is due to the fact that single amino acid substitutions within the NNRTI binding pocket can dramatically reduce the drug's binding affinity. Key mutations associated with Delavirdine resistance include K103N, Y181C, Y188L, and P236L.[11] The K103N mutation, in particular, is a major pathway for NNRTI resistance and confers broad cross-resistance to other agents in the class, such as nevirapine and efavirenz.[1] This risk of cross-resistance severely limits the sequential use of NNRTIs and underscores the absolute requirement to use Delavirdine only as part of a combination antiretroviral regimen to maximally suppress viral replication and prevent the emergence of resistant variants.[8]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical behavior of Delavirdine is heavily influenced by its distinct pharmacokinetic properties, particularly its pH-dependent absorption and its complex, non-linear metabolism involving auto-inhibition of CYP450 enzymes.

Absorption and Bioavailability

Delavirdine is rapidly absorbed after oral administration, with peak plasma concentrations (Tmax​) achieved approximately one hour post-dose.[7] The absolute oral bioavailability of the tablet formulation is approximately 85% relative to an oral solution.[1]

A defining feature of its absorption is the dependency on an acidic gastric environment, a direct consequence of its poor aqueous solubility at neutral or alkaline pH.[11] This property necessitates specific clinical guidance: co-administration with agents that increase gastric pH, such as antacids, histamine

H2​-receptor antagonists, or proton pump inhibitors, can significantly reduce Delavirdine absorption and should be avoided or carefully timed.[3] In patients with achlorhydria (absence of stomach acid), it is recommended that Delavirdine be taken with an acidic beverage, such as orange or cranberry juice, to facilitate dissolution and absorption.[24]

The drug can be administered with or without food. While taking Delavirdine with a meal can reduce its peak concentration (Cmax​) by about 25%, it does not significantly impact the overall systemic exposure (Area Under the Curve, AUC) or the trough concentration (Cmin​).[7] The 100 mg tablets have the unique property of being dispersible in water; preparing a slurry by this method can increase bioavailability by approximately 20%. In contrast, the 200 mg tablets do not disperse readily and must be swallowed whole.[17]

Distribution

Following absorption, Delavirdine is extensively bound to plasma proteins, with approximately 98% bound primarily to albumin.[1] This high degree of protein binding limits the amount of free, active drug available to penetrate tissues. Consequently, its distribution into key viral sanctuary sites is limited. Concentrations in the cerebrospinal fluid (CSF) are very low, averaging only 0.4% of corresponding plasma concentrations.[7] While this represents about 20% of the unbound fraction of the drug, the clinical significance of such low levels is uncertain. Similarly, concentrations in saliva and semen are approximately 6% and 2%, respectively, of plasma levels.[7]

Metabolism

Delavirdine undergoes extensive hepatic metabolism into several inactive metabolites.[7] The primary metabolic pathway is mediated by the cytochrome P450 3A4 (CYP3A4) isoenzyme, with a potential minor contribution from CYP2D6.[7] The major biotransformation reactions are N-dealkylation and pyridine hydroxylation.[7]

A critical aspect of Delavirdine's pharmacology is its non-linear, dose-dependent elimination kinetics.[7] As the daily dose of Delavirdine increases, its apparent oral clearance decreases dramatically. This phenomenon is due to auto-inhibition; Delavirdine is a potent inhibitor of its own primary metabolizing enzyme, CYP3A4.[7] This self-inhibitory effect complicates its dosing, contributes to significant inter-patient variability in plasma concentrations, and is the mechanistic basis for its extensive drug-drug interaction profile. The inhibition of CYP3A4 is reversible, with enzyme activity typically returning to baseline within one week of discontinuing the drug.[7]

Excretion

The elimination of Delavirdine occurs primarily through its metabolites. Less than 5% of an administered dose is excreted as unchanged drug in the urine.[7] Following administration of a radiolabeled dose, approximately 51% of the radioactivity is recovered in the urine and 44% is recovered in the feces, reflecting the clearance of its various metabolites.[7] The mean elimination half-life (

t1/2​) at the recommended dose of 400 mg three times daily is approximately 5.8 hours, though it exhibits a wide range of 2 to 11 hours, a variability consistent with its non-linear, auto-inhibitory metabolism.[1]

Table 1: Summary of Delavirdine's Pharmacokinetic Parameters

Parameter	Value	Source(s)
Bioavailability	~85%	1
Time to Peak Concentration (Tmax​)	~1 hour	8
Food Effect	Cmax​ reduced ~25%; AUC and Cmin​ unchanged	17
Plasma Protein Binding	~98% (primarily albumin)	21
CSF:Plasma Ratio	~0.4%	7
Primary Metabolic Pathway	Hepatic; Cytochrome P450 3A4 (major), CYP2D6 (minor)	7
Elimination Half-Life (t1/2​)	5.8 hours (range: 2-11 hours)	7
Excretion Routes	51% in urine (as metabolites), 44% in feces (as metabolites)	7
Unchanged Drug in Urine	<5%	7

Clinical Application: Efficacy, Dosage, and Administration

Therapeutic Indications and Clinical Efficacy

Delavirdine is indicated for the treatment of HIV-1 infection, but only when used in combination with other appropriate antiretroviral agents.[2] The original FDA approval was granted based on the drug's ability to effect changes in surrogate markers of disease progression—namely, reductions in plasma HIV-1 RNA levels and increases in CD4+ T-cell counts.[8] Clinical studies demonstrated that triple-therapy regimens containing Delavirdine plus two NRTIs (e.g., zidovudine and didanosine) resulted in more durable virologic suppression compared to dual-NRTI therapy alone. In one pivotal trial, after 50 weeks of treatment, 40% of patients receiving a Delavirdine-based triple therapy achieved plasma HIV RNA levels below the limit of detection (<50 copies/mL), compared to only 6% of those receiving dual NRTI therapy.[6] These regimens also led to corresponding increases in CD4 cell counts, indicating a degree of immunological benefit.[6]

However, the clinical standing of Delavirdine was compromised from the outset. The drug's own prescribing information contains a prominent warning stating that its indication is based on these surrogate marker changes and that a definitive clinical benefit, as measured by survival or the incidence of AIDS-defining clinical events, was not demonstrated in a key trial comparing Delavirdine plus didanosine to didanosine monotherapy.[8] This approval history reflects a specific moment in the evolution of drug regulation, particularly for life-threatening conditions like HIV/AIDS in the 1990s. The FDA's "fast track" process allowed for approvals based on promising biomarker data, a necessary step to bring new agents to patients in urgent need.[27] Yet, the case of Delavirdine illustrates the potential pitfalls of this approach. While it met the regulatory standard of the time, it failed to meet the evolving clinical standard in a rapidly advancing field.

In direct comparisons and clinical practice, Delavirdine was found to have lower virologic efficacy than other NNRTIs, especially efavirenz.[1] This, combined with its inconvenient three-times-daily dosing schedule and high pill burden, led major treatment guideline bodies, such as the U.S. Department of Health and Human Services (DHHS), to not recommend its use as a component of initial antiretroviral therapy.[1] Its potential role in second-line or salvage regimens was also severely limited by the high risk of cross-resistance across the NNRTI class and its exceptionally complex drug interaction profile. As a result, Delavirdine was rarely used in clinical practice, having been superseded by agents that offered a superior combination of potency, durability, tolerability, and convenience.[1]

Dosage and Administration

The standard recommended dosage of Delavirdine for adults and adolescents (16 years of age and older) is 400 mg administered orally three times daily.[1] A twice-daily regimen of 600 mg was also investigated and found to provide comparable systemic exposure, but the three-times-daily regimen remained the standard.[3] Delavirdine was supplied in 100 mg and 200 mg tablets.[21]

Specific administration guidelines are critical for ensuring proper absorption and avoiding interactions:

• Food: Delavirdine may be taken with or without food.[23]
• Tablet Dispersion: The 100 mg tablets can be dispersed in at least 3 ounces (90 mL) of water to form a slurry for patients who have difficulty swallowing tablets. The mixture should be consumed immediately, and the glass rinsed to ensure the full dose is taken. The 200 mg tablets are smaller, do not disperse well, and should be swallowed whole.[26]
• Acid-Reducing Agents: Due to the requirement of an acidic environment for absorption, Delavirdine must be administered at least one hour apart from antacids.[21] Long-term use with H2-receptor antagonists or proton pump inhibitors is not recommended.[21]
• Achlorhydria: Patients with achlorhydria should take Delavirdine with an acidic beverage like orange or cranberry juice.[24]
• Didanosine: The buffered formulations of didanosine can interfere with Delavirdine absorption. Administration of these two drugs should be separated by at least one hour.[21]

Safety and Tolerability Profile

The use of Delavirdine is associated with a distinct safety and tolerability profile, dominated by dermatologic reactions and the potential for hepatotoxicity. Its overall adverse event profile contributed to its limited clinical use.

Common Adverse Reactions

The most frequently reported adverse event and the primary toxicity associated with Delavirdine is a skin rash. This rash, typically described as maculopapular and pruritic, occurs in up to 35% of patients.[1] It most commonly appears within the first one to three weeks of initiating therapy and is often mild to moderate in severity.[2] In many cases, the rash resolves within two weeks, sometimes even with continued treatment, and does not require dose adjustment or discontinuation.[2] The incidence of rash appears to be higher in patients with lower baseline CD4+ cell counts.[21]

Other common adverse reactions include:

• Constitutional and Central Nervous System (CNS) Effects: Fatigue, headache, and asthenia (weakness) are frequently reported.[1]
• Gastrointestinal (GI) Effects: Nausea, diarrhea, and vomiting are common GI complaints.[1]
• Metabolic Effects: Like many early antiretroviral agents, Delavirdine has been associated with redistribution and/or accumulation of body fat (lipodystrophy), characterized by central obesity, peripheral wasting, and breast enlargement.[22]

Severe and Clinically Significant Adverse Events

While most adverse events are manageable, Delavirdine can cause severe and potentially life-threatening reactions.

• Severe Rash and Hypersensitivity Reactions: Although typically mild, the rash can progress to a severe form (Grade 3, involving vesiculation, moist desquamation, or ulceration) in approximately 3.6% of patients.[21] The development of a severe rash, or any rash accompanied by systemic symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, or muscle and joint aches, constitutes a hypersensitivity reaction and requires immediate discontinuation of the drug.[15] Rare cases of erythema multiforme and Stevens-Johnson syndrome have been reported.[29]
• Hepatotoxicity: Delavirdine is associated with liver toxicity.[1] Asymptomatic elevations in serum aminotransferases (ALT and AST) are common, occurring in 25% or more of patients.[2] Clinically significant elevations (more than five times the upper limit of normal) occur in 4% or less of patients, with a higher risk observed in individuals with chronic hepatitis C virus (HCV) co-infection.[2] While clinically apparent acute liver injury is rare, cases of hepatitis, jaundice, and hepatic failure have been reported to the manufacturer and are noted in the product labeling.[2] The mechanism of hepatotoxicity is thought to be an immunoallergic reaction, similar to that seen with other NNRTIs like nevirapine, typically occurring within the first 1 to 8 weeks of therapy and often accompanied by signs of hypersensitivity (rash, fever, eosinophilia).[2]
• Postmarketing Reports: Surveillance after the drug's approval has identified other rare but serious adverse events, including hemolytic anemia, rhabdomyolysis, and acute kidney failure.[30]

Contraindications, Precautions, and Warnings

Delavirdine is contraindicated in patients with a known hypersensitivity to the drug or any of its components.[22] However, the most critical contraindications relate to its potent inhibition of CYP3A4. It must not be co-administered with a range of drugs that are highly dependent on this enzyme for their clearance and for which elevated plasma concentrations are associated with serious or life-threatening events. These contraindicated drugs include certain benzodiazepines (alprazolam, midazolam, triazolam), ergot alkaloids, HMG-CoA reductase inhibitors (simvastatin, lovastatin), the GI motility agent cisapride, and others.[1]

Precautions for its use include cautious administration in patients with impaired hepatic function, as its metabolism may be reduced, leading to increased exposure.[21] The safety and effectiveness of Delavirdine have not been established in pediatric patients younger than 16 years or in geriatric patients older than 65 years.[18]

The prescribing information for Delavirdine does not contain a formal FDA "Black Box Warning".[31] However, the 1999 product label features a prominent "WARNING" section at the top of the document, a distinct regulatory presentation. This warning emphasizes two key points: 1) the rapid emergence of resistant virus when Delavirdine is used as monotherapy, mandating its use only in combination with other appropriate antiretrovirals, and 2) the fact that its approval was based on changes in surrogate markers, with clinical benefit on survival or AIDS-defining events not having been demonstrated in a key clinical trial.[8]

Table 2: Adverse Drug Reactions Associated with Delavirdine by System Organ Class and Frequency

System Organ Class	Adverse Reaction	Frequency	Source(s)
Dermatologic	Rash (maculopapular, pruritic)	Very Common (up to 35.4%)	29
	Severe Rash (Grade 3)	Common (3.6%)	21
	Stevens-Johnson Syndrome	Rare	29
Gastrointestinal	Nausea	Very Common (up to 20.3%)	29
	Diarrhea, Vomiting	Common	1
Nervous System	Headache	Very Common (up to 16.8%)	29
	Fatigue, Asthenia	Very Common (up to 16%)	1
Hepatic	Increased ALT/AST	Common (>10%)	2
	ALT/AST >5x ULN	Common (up to 5.1%)	2
	Hepatic Failure	Postmarketing	29
Psychiatric	Depressive Symptoms	Very Common (up to 12.6%)	29
	Insomnia, Anxiety	Common (1-10%)	29
Hematologic	Neutropenia (<750/mm³)	Common (up to 7.6%)	21
	Hemolytic Anemia	Postmarketing	30
Metabolic	Redistribution/Accumulation of Body Fat	Frequency Not Reported	22
Musculoskeletal	Rhabdomyolysis	Postmarketing	29
Urogenital	Acute Kidney Failure	Postmarketing	30

Drug Interaction Profile: A Cytochrome P450 Inhibitor

The clinical utility of Delavirdine is overwhelmingly defined by its complex and extensive drug-drug interaction profile. This profile is rooted in its potent inhibition of key metabolic enzymes, a characteristic that sets it apart from other early NNRTIs and dictates stringent limitations on its co-administration with a wide array of medications.

Mechanism of Interactions

The primary mechanism driving Delavirdine's interactions is its role as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme.[1] This is in stark contrast to other NNRTIs like nevirapine and efavirenz, which are primarily inducers of this pathway.[3] By inhibiting CYP3A4, Delavirdine can significantly increase the plasma concentrations of other drugs that are metabolized by this enzyme, potentially leading to increased therapeutic effects or, more critically, severe toxicity. Delavirdine also demonstrates weaker, but potentially clinically relevant, inhibition of other isoforms, including CYP2C9, CYP2C19, and CYP2D6.[7]

A secondary mechanism of interaction arises from its pH-dependent absorption. Co-administration with drugs that raise gastric pH, such as antacids and H2-receptor antagonists, can impair the dissolution and absorption of Delavirdine, leading to lower plasma concentrations and a risk of sub-therapeutic dosing and viral resistance.[3]

Pharmacokinetic Enhancer ("Booster")

The potent inhibition of CYP3A4 by Delavirdine can be therapeutically leveraged. Many HIV protease inhibitors are substrates of CYP3A4, and their co-administration with Delavirdine can lead to a significant increase in their plasma concentrations. This "boosting" effect was demonstrated in pharmacokinetic studies, where Delavirdine was shown to increase the AUC of saquinavir five-fold and to substantially increase the levels of indinavir and ritonavir.[3] This interaction offered the potential to simplify protease inhibitor regimens, for example, by allowing for lower doses or removing food restrictions associated with indinavir administration.[3] This property made Delavirdine unique among NNRTIs, positioning it as a potential alternative to ritonavir for pharmacokinetic enhancement.

Clinically Significant Interactions and Contraindications

Despite its potential as a booster, the broad inhibitory effects of Delavirdine result in a far greater number of clinically prohibitive or dangerous interactions. The risk of causing severe toxicity by elevating the levels of co-administered drugs led to a long list of contraindications and warnings.

• CYP3A4 Inducers: Conversely, Delavirdine's therapeutic efficacy is threatened by co-administration with potent CYP3A4 inducers. Drugs such as rifampin, rifabutin, carbamazepine, phenobarbital, phenytoin, and the herbal product St. John's wort can significantly accelerate the metabolism of Delavirdine, leading to dangerously low plasma concentrations, loss of virologic response, and the rapid emergence of NNRTI-resistant HIV-1.[1] Co-administration with these agents should be avoided.

Table 3: Clinically Significant Drug-Drug Interactions with Delavirdine

Interacting Drug/Class	Effect on Interacting Drug	Effect on Delavirdine	Clinical Recommendation	Mechanism	Source(s)
Benzodiazepines (Alprazolam, Midazolam, Triazolam)	↑ Concentration	No change	CONTRAINDICATED	CYP3A4 Inhibition	1
Ergot Alkaloids (Ergotamine, etc.)	↑ Concentration	No change	CONTRAINDICATED	CYP3A4 Inhibition	1
HMG-CoA Reductase Inhibitors (Simvastatin, Lovastatin)	↑ Concentration	No change	CONTRAINDICATED	CYP3A4 Inhibition	1
GI Motility Agent (Cisapride)	↑ Concentration	No change	CONTRAINDICATED	CYP3A4 Inhibition	18
CYP3A4 Inducers (Rifampin, Phenytoin, St. John's Wort)	Variable	↓ Concentration	AVOID USE	CYP3A4 Induction	1
HIV Protease Inhibitors (Saquinavir, Indinavir)	↑ Concentration	Variable	Dose adjustment may be needed	CYP3A4 Inhibition	3
Acid-Reducing Agents (Antacids, H2-Antagonists)	No change	↓ Absorption	Separate doses by ≥1 hour; Avoid chronic H2-blocker use	Increased Gastric pH	3
Calcium Channel Blockers (Amlodipine, Nifedipine, etc.)	↑ Concentration	No change	Use with caution; Monitor	CYP3A4 Inhibition	7
Antiarrhythmics (Amiodarone, Quinidine, etc.)	↑ Concentration	No change	Use with caution; Monitor levels	CYP3A4 Inhibition	7
Immunosuppressants (Cyclosporine, Tacrolimus)	↑ Concentration	No change	Use with caution; Monitor levels	CYP3A4 Inhibition	7
Anticoagulant (Warfarin)	↑ Concentration	No change	Monitor INR	CYP2C9 Inhibition	7
Erectile Dysfunction Agents (Sildenafil)	↑ Concentration	No change	Reduce sildenafil dose	CYP3A4 Inhibition	7

Regulatory History and Market Discontinuation

FDA Approval Timeline

Delavirdine mesylate, under the brand name Rescriptor, was developed by Pharmacia & Upjohn. It received its initial approval from the U.S. Food and Drug Administration (FDA) on April 4, 1997.[1] This approval was for the 100 mg tablet formulation and positioned Delavirdine as a new therapeutic option within the NNRTI class for use in combination HIV-1 therapy.[34]

The approval process was not without controversy. It proceeded under the FDA's "fast track" initiative, designed to expedite the availability of drugs for serious and life-threatening conditions.[27] However, clinical data presented to the FDA's scientific advisory panel were conflicting, leading to a deadlock among the advisors in November 1996. While some studies showed a modest benefit when combined with AZT, another study in severely ill patients showed the benefit was short-lived.[27]

Following the initial approval, a 200 mg tablet formulation was approved on July 14, 1999.[36] Over the subsequent years, the manufacturer submitted several supplemental applications to the FDA, which were approved to update the prescribing information. For instance, an approval on August 16, 1999, incorporated changes to the WARNINGS and PRECAUTIONS sections to include new data on significant drug-drug interactions with sildenafil and the protease inhibitor amprenavir.[17] Another label update was approved on May 16, 2001.[37]

Decline in Clinical Use and Discontinuation

Despite its approval and unique pharmacological profile, Delavirdine failed to secure a significant or lasting place in clinical practice. Its decline was multifactorial and swift, driven by the rapid pace of innovation in antiretroviral therapy. The key factors contributing to its obsolescence were:

1. Inferior Virologic Efficacy: Head-to-head clinical data and subsequent experience demonstrated that Delavirdine was less potent than other available NNRTIs, particularly efavirenz.[1]
2. Inconvenient Dosing Regimen: The requirement for three-times-daily dosing was a significant disadvantage compared to the once-daily regimens that were becoming the standard of care, negatively impacting patient adherence and quality of life.[1]
3. High Pill Burden: The 400 mg dose required taking multiple tablets at each administration, further complicating the regimen.[23]
4. Complex and Risky Drug Interaction Profile: As detailed previously, its potent inhibition of CYP3A4 created a high potential for numerous, clinically significant drug-drug interactions, making it difficult and hazardous to use in patients who were often on multiple concomitant medications for opportunistic infections or other comorbidities.[1]
5. Low Genetic Barrier to Resistance: The rapid emergence of viral mutations that conferred cross-resistance to the entire NNRTI class made it a poor choice for long-term strategic management of HIV.[13]

These collective disadvantages led to Delavirdine being rarely prescribed. In May 2017, the manufacturer at the time, ViiV Healthcare, officially announced the decision to discontinue the production of Delavirdine. The existing supply was expected to be depleted by October 2018.[38]

Rationale for Market Withdrawal

The discontinuation of Delavirdine was explicitly stated to be a business decision based on low and declining market demand.[39] The manufacturer clarified that the withdrawal was not prompted by any new or unresolved concerns regarding the product's quality, safety, or efficacy.[39] Essentially, Delavirdine had been rendered obsolete by the development and widespread adoption of superior antiretroviral agents. Today, Delavirdine is no longer marketed or available in the United States, and no generic versions are produced.[36]

Concluding Analysis: The Legacy of Delavirdine

Delavirdine occupies a unique and instructive chapter in the history of antiretroviral therapy. It was a scientifically rational drug, born of the urgent need for new mechanisms to combat HIV-1 during the transformative HAART era of the mid-1990s. Its approval, based on surrogate marker data, reflected a regulatory environment rightly focused on expediting access to potentially life-saving treatments. However, its story is ultimately one of clinical failure, not due to a lack of initial scientific promise, but because its overall profile could not compete in a therapeutic landscape characterized by relentless and rapid innovation.

The principal strength of Delavirdine was its novel pharmacology. As an NNRTI, it provided an alternative to nucleoside analogues, and its unique status as a potent CYP3A4 inhibitor offered the intriguing possibility of serving as a pharmacokinetic enhancer for protease inhibitors. This dual functionality made it a subject of considerable pharmacological interest. Yet, this very strength was inextricably linked to its fatal flaw.

The drug's insurmountable weaknesses were numerous and decisive. Its modest virologic efficacy was quickly surpassed by more potent alternatives. Its inconvenient three-times-daily dosing schedule and high pill burden stood in stark contrast to the simpler, adherence-friendly regimens that would come to define modern HIV care. The high incidence of rash, while often manageable, added to its tolerability burden. Most importantly, its profound and complex drug interaction profile, a direct result of its CYP450 inhibition, rendered it a clinical liability. The constant need for vigilance, dose adjustments, and the avoidance of numerous common medications made its safe use a formidable challenge.

The lifecycle of Delavirdine offers powerful lessons for modern drug development. It underscores that for the management of a chronic disease like HIV, therapeutic success is a multidimensional construct. It is determined not merely by a drug's primary mechanism of action or its effect on a biomarker, but by the totality of its clinical profile: superior efficacy, long-term safety, high tolerability, convenience of administration, and a predictable, manageable interaction profile. Delavirdine's journey from a promising new agent to a rarely used medication and finally to discontinuation is a testament to the high bar set by continuous innovation in antiretroviral therapy. While no longer in clinical use, it remains a valuable case study for pharmacologists and clinicians on the critical and often decisive impact of a drug's metabolic properties on its ultimate therapeutic destiny.

Works cited

1. Delavirdine - Wikipedia, accessed September 18, 2025, https://en.wikipedia.org/wiki/Delavirdine
2. Delavirdine - LiverTox - NCBI Bookshelf, accessed September 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547899/
3. Delavirdine: clinical pharmacokinetics and drug interactions - PubMed, accessed September 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11327199/
4. Approved HIV reverse transcriptase inhibitors in the past decade - PMC - PubMed Central, accessed September 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9279714/
5. Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed September 18, 2025, https://journals.asm.org/doi/10.1128/aac.47.5.1694-1699.2003
6. Delavirdine: a review of its use in HIV infection - PubMed, accessed September 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11152019/
7. RESCRIPTOR - accessdata.fda.gov, accessed September 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf
8. 1 RESCRIPTOR 1 brand of delavirdine mesylate tablets 2 3 WARNING - accessdata.fda.gov, accessed September 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20705s03lbl.pdf
9. Delavirdine tablets - Cleveland Clinic, accessed September 18, 2025, https://my.clevelandclinic.org/health/drugs/19667-delavirdine-tablets
10. Delavirdine | CAS NO.:136817-59-9 | GlpBio, accessed September 18, 2025, https://www.glpbio.com/gc35835.html
11. CAS 136817-59-9 Delavirdine - BOC Sciences, accessed September 18, 2025, https://www.bocsci.com/product/delavirdine-cas-136817-59-9-57976.html
12. Delavirdine | U 90152 | NNRT inhibitor | Axon 1815, accessed September 18, 2025, https://www.axonmedchem.com/1815_Delavirdine
13. Delavirdine | C22H28N6O3S | CID 5625 - PubChem, accessed September 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Delavirdine
14. Delavirdine - brand name list from Drugs.com, accessed September 18, 2025, https://www.drugs.com/ingredient/delavirdine.html
15. Delavirdine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 18, 2025, https://go.drugbank.com/drugs/DB00705
16. Delavirdine | NNRTI | CAS#136817-59-9 | MedKoo, accessed September 18, 2025, https://www.medkoo.com/products/7532
17. center for drug evaluation and research - accessdata.fda.gov, accessed September 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020705_S004_Rescriptor%20Tablets_APPROVAL%20PACKAGE.pdf
18. RESCRIPTOR - GSKPro for Healthcare Professionals, accessed September 18, 2025, https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Rescriptor/pdf/RESCRIPTOR-PI-PIL.PDF
19. RESCRIPTOR® (brand of delavirdine mesylate tablets) - accessdata.fda.gov, accessed September 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020705_S008_Rescriptor%20Tablets_PRNTLBL.pdf
20. Antiretroviral Therapy for HIV Infection - Medscape Reference, accessed September 18, 2025, https://emedicine.medscape.com/article/1533218-overview
21. delavirdine mesylate, accessed September 18, 2025, https://www.glowm.com/resources/glowm/cd/pages/drugs/d011.html
22. Delavirdine | Davis's Drug Guide for Rehabilitation Professionals, accessed September 18, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139007467
23. DELAVIRDINE, accessed September 18, 2025, https://hivclinic.ca/main/drugs_fact_files/delavirdine.pdf
24. Rescriptor Dosage Guide - Drugs.com, accessed September 18, 2025, https://www.drugs.com/dosage/rescriptor.html
25. Delavirdine (oral route) - Side effects & dosage - Mayo Clinic, accessed September 18, 2025, https://www.mayoclinic.org/drugs-supplements/delavirdine-oral-route/description/drg-20063399
26. Delavirdine: MedlinePlus Drug Information, accessed September 18, 2025, https://medlineplus.gov/druginfo/meds/a600034.html
27. FDA Approves Controversial AIDS Drug - Time Magazine, accessed September 18, 2025, https://time.com/archive/6930005/fda-approves-controversial-aids-drug/
28. Delavirdine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 18, 2025, https://www.drugs.com/dosage/delavirdine.html
29. Delavirdine Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 18, 2025, https://www.drugs.com/sfx/delavirdine-side-effects.html
30. Side Effects of Rescriptor (delavirdine): Interactions & Warnings - MedicineNet, accessed September 18, 2025, https://www.medicinenet.com/side_effects_of_delavirdine/side-effects.htm
31. Nevirapine - Wikipedia, accessed September 18, 2025, https://en.wikipedia.org/wiki/Nevirapine
32. Boxed Warning 11/2008 - accessdata.fda.gov, accessed September 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021356s027lbl.pdf
33. Box Warning - StatPearls - NCBI Bookshelf, accessed September 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK538521/
34. Delavirdine gets FDA approval | 1997-06-01 | AHC… | Clinician.com, accessed September 18, 2025, https://www.clinician.com/articles/48979-delavirdine-gets-fda-approval
35. pubmed.ncbi.nlm.nih.gov, accessed September 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11327199/#:~:text=Concomitant%20use%20of%20CYP%20inducers,plasma%20concentrations%20are%20significantly%20lowered.
36. Generic Rescriptor Availability - Drugs.com, accessed September 18, 2025, https://www.drugs.com/availability/generic-rescriptor.html
37. Drug Approval Package: Rescriptor (Delavirdine Mesylate) NDA #020705s008, accessed September 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020705_S008_RescriptorTOC.cfm
38. Rescriptor (delavirdine) dosing, indications, interactions, adverse effects, and more, accessed September 18, 2025, https://reference.medscape.com/drug/rescriptor-delavirdine-342607
39. Rescriptor (delavirdine): Drug Basics and Frequently Asked Questions - GoodRx, accessed September 18, 2025, https://www.goodrx.com/rescriptor/what-is
40. Rescriptor (delavirdine mesylate) – Product discontinuation, accessed September 18, 2025, https://prod-prorx.optum.com/content/dam/optum3/professional-optumrx/news/rxnews/drug-recalls-shortages/drugwithdrawal_rescriptor_2017-0515.pdf
41. Delavirdine - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed September 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK501544/